Cradle Bio

Executive Summary

Cradle Bio, a Dutch biotechnology startup founded in 2021, leverages artificial intelligence to revolutionize protein engineering. Its platform generates and optimizes protein candidates for desired properties such as stability, binding affinity, and expression, significantly accelerating R&D timelines from years to quarters. By integrating customer experimental data into its AI-driven design loop, Cradle enables more efficient and targeted protein development, addressing key bottlenecks in biotherapeutics, industrial enzymes, and diagnostics. The company operates in a rapidly growing AI-driven drug discovery market, with strong potential to partner with pharmaceutical and biotech firms seeking faster protein optimization. Cradle's differentiated approach—combining generative models with iterative learning from wet-lab feedback—positions it as a leader in the space. With a solid founding team and Amsterdam's vibrant biotech ecosystem, Cradle Bio is poised to capture significant value, though execution and commercial validation remain key risks.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Funding Round Closing80% success
• Q1 2027Major Pharmaceutical Partnership Announcement50% success
• Q4 2026Platform Update with Enhanced Protein Design Capabilities70% success